Core Viewpoint - The financial performance of Weining Health (300253) for the first half of 2025 shows significant declines in revenue and profit, indicating challenges in business operations and financial health [1][3]. Financial Performance Summary - Total revenue for the first half of 2025 was 839 million yuan, a decrease of 31.43% year-on-year [1]. - The net profit attributable to shareholders was -118 million yuan, representing a decline of 491.04% compared to the previous year [1]. - In Q2 2025, total revenue was 494 million yuan, down 32.24% year-on-year, with a net profit of -123 million yuan, a staggering drop of 1009.8% [1]. - The gross margin was 36.41%, down 12.02% year-on-year, while the net margin was -14.64%, a decrease of 906.27% [1]. - The total of selling, administrative, and financial expenses reached 231 million yuan, accounting for 27.53% of revenue, an increase of 14.81% year-on-year [1]. - The company reported a significant increase in accounts receivable, which accounted for 1137.98% of the latest annual net profit [1][3]. Cash Flow and Financial Ratios - The operating cash flow per share was 0.02 yuan, an increase of 161.93% year-on-year, while earnings per share were -0.05 yuan, a decrease of 482.14% [1]. - The company’s return on invested capital (ROIC) was 1.54%, indicating weak capital returns, with a historical median ROIC of 9.09% over the past decade [3]. - The net profit margin for the previous year was 1.8%, suggesting low added value in products or services [3]. Fund Holdings - The largest fund holding Weining Health is the Nuon Active Return Mixed A fund, which has reduced its holdings [4]. - Other funds, such as Guorong Rongsheng Longtou Selected Mixed A and Yifangda Yuxin Bond A, have increased their positions in the company [4]. - The current scale of the Nuon fund is 1.487 billion yuan, with a recent net value increase of 4.42% [4].

截至发稿，卫宁健康市值为242亿元。 每经头条（nbdtoutiao）——汽车涂料龙头"命悬一线"，资金流向成迷，掌控者深藏不露 （记者 张明双） 每经AI快讯，卫宁健康（SZ 300253，收盘价：10.92元）8月22日晚间发布公告称，公司第六届第十六 次董事会会议于2025年8月21日在公司会议室以现场和通讯相结合的表决方式召开。会议审议了《关于 <公司2025年半年度报告及其摘要> 的议案》等文件。 2025年1至6月份，卫宁健康的营业收入构成为：医疗卫生信息化行业占比92.54%，互联网医疗健康行 业占比7.46%。 ...

Core Viewpoint - Weining Health's stock price increased by 4.30% to 10.92 yuan as of August 22, 2025, despite a significant decline in revenue and net profit in the first half of the year [1]. Company Summary - Weining Health operates in the software development industry, focusing on healthcare information technology, providing medical information solutions and related technical services [1]. - The company reported a revenue of 839 million yuan for the first half of 2025, representing a year-on-year decrease of 31.43% [1]. - The net profit attributable to shareholders was a loss of 118 million yuan, a year-on-year decline of 491.04% [1]. - The company announced it has paid back tax and late fees totaling 57.37 million yuan, which is expected to impact the net profit for the year 2025 [1]. - On August 22, the net inflow of main funds was 92.146 million yuan, accounting for 0.44% of the circulating market value; however, over the past five days, there was a net outflow of 120.562 million yuan, representing 0.58% of the circulating market value [1].

北京商报讯（记者 丁宁）8月22日晚间，卫宁健康（300253）发布2025年半年报显示，公司营业收入为 8.39亿元，同比下降31.43%；归属净利润-1.18亿元，同比下降491.04%。 卫宁健康表示，报告期经营业绩下滑的主要原因是部分客户需求释放递延、WiNEX产品在升级替换过 程中尚未转化为规模收入、人工等成本费用相对刚性，以及互联网医疗健康业务优化（部分关停或剥 离）、资产减值损失、补缴税款及滞纳金等。 ...

Group 1 - The company reported a revenue of 839 million yuan and a net profit attributable to shareholders of -118 million yuan for the first half of 2025, with a significant increase in operating cash flow by 163.44% to 53.79 million yuan [1] - The company has strengthened its leading position in the medical information industry through the excellent performance of its core product WiNEX series and active layout in AI large model technology and domestic replacement [1] - The company has optimized the performance of WiNEX products, completing over 90 business decouplings and more than 100 model optimizations, establishing a lightweight foundation for agile business assembly [1] Group 2 - The company launched AI models WiNGPT 3.0 and WiNEX Copilot 2.2 in May 2025, which have been deployed in nearly 150 medical institutions, enhancing AI technology applications in the medical field [2] - The company has actively responded to policy guidance and market demand in domestic replacement, achieving deep adaptation of domestic chips and completing compatibility certification for its entire product line with the Longxin 3A6000 processor [2] - The company has assisted multiple hospitals in completing domestic replacement deployments, establishing practical benchmarks for regional medical resource integration and domestic transformation [2] Group 3 - The company has been providing integrated solutions in medical health information since its establishment, focusing on enhancing patient experience and health levels through continuous technological innovation [3] - The company's business covers various fields including smart hospitals, regional health, grassroots health, public health, medical insurance, and health services, making it a competitive supplier in China's medical health information industry [3]

格隆汇8月22日丨卫宁健康(300253.SZ)公布半年度报告，报告期内，公司实现营业收入83,915.09万元， 同比下降31.43%；归属于上市公司股东的净利润-11,796.98万元，同比下降491.04%；归属于上市公司股 东的扣除非经常性损益的净利润-9,982.16万元，同比下降564.73%。报告期内，公司医疗卫生信息化业 务收入77,652.05万元，同比下降25.76%，占营业收入比重为92.54%（上年同期为85.48%）。其中：核 心产品软件销售及技术服务业务收入71,031.41万元，同比下降21.22%，占营业收入比重为84.65%（上 年同期为73.68%）；硬件销售业务收入6,620.65万元，同比下降54.15%，占营业收入比重为7.89%（上 年同期为11.80%）。互联网医疗健康业务收入6,262.56万元，同比下降64.76%，占营业收入比重为 7.46%（上年同期为14.52%）。公司产品策略进一步向核心业务聚焦，核心业务收入占营业收入比重逐 渐提升。报告期经营业绩下滑的主要原因是部分客户需求释放递延、WiNEX产品在升级替换过程中尚 未转化为规模收入、人工等成本费用相 ...

2025 年半年度非经营性资金占用及其他关联资金往来情况汇总表 卫宁健康科技集团股份有限公司 | | | | 编制单位：卫宁健康科技集团股份有限公司 | | | | | 2025 年 1 月 1 日至 | 2025 年 1 月 1 日 | 2025 年 1 月 1 | 日 | | 单位：万元 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占用 | 资金占用方名称 | 占用方与上市 公司的关联关 | 上市公司核算 的会计科目 | 2025 年初往来 资金余额 | 2025 年 6 月 30 日 止往来累计发生金 | 至 2025 年 6 月 30 日止往来资金的 | 至 2025 年 6 月 日止偿还累计发 | 2025 年 6 月 30 30 日往来资 | 占用形成原因 | 占用性质 | | | | 系 | | | 额(不含利息) | 利息(如有) | 生金额 | 金余额 | | | | 控股股东、实际控制人及其 | | | | | | | | | | 非经营性占用 | | 附属企业 | | | | ...

证券代码：300253 证券简称：卫宁健康 公告编号：2025-066 卫宁健康科技集团股份有限公司 经中国证券监督管理委员会《关于同意卫宁健康科技集团股份有 限公司向不特定对象发行可转换公司债券注册的批复》（证监许可 ［2021］311 号）核准，公司获准向不特定对象发行可转换公司债券 970.2650 万张，每张面值为人民币 100 元，按面值发行，募集资金 总额为人民币 970,265,000.00 元，扣除各项发行费用不含税金额合 计 人 民 币 9,055,377.36 元 后 ， 实 际 募 集 资 金 净 额 为 人 民 币 961,209,622.64 元。该募集资金已于 2021 年 3 月 22 日到账。上述 资金到账情况已于 2021 年 3 月 23 日经容诚会计师事务所（特殊普通 合伙）"容诚验字[2021]200Z0016 号"《验资报告》验证。公司对募 集资金采取了专户存储管理。 （二）募集资金使用及结余情况 截至2025年6月30日止，公司可转债募集资金使用情况如下： 单位：万元 | 项目 | 金额 | | --- | --- | | 募集资金总额 | 97,026.50 | ...

证券代码：300253 证券简称：卫宁健康 公告编号：2025-067 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 卫宁健康科技集团股份有限公司 卫宁健康科技集团股份有限公司（以下简称"公司"）根据《企 业会计准则》及会计政策的相关规定，对 2025 年半年度财务报告合 并报表范围内相关资产计提减值准备。现将具体情况公告如下： 关于 2025 年半年度计提减值准备的公告 一、本次计提减值准备情况概述 公 司 2025 年 半 年 度 对 相 关 资 产 计 提 减 值 准 备 共 计 83,045,752.96 元，具体如下： | 类别 | 项目 | 本期发生额（元） | | --- | --- | --- | | | 应收票据坏账准备 | 339,920.00 | | 信用减值准备（损失以 | 应收账款坏账准备 | 4,744,890.64 | | "_"填列） | 其他应收款坏账准备 | -1,171,831.03 | | | 长期应收款坏账准备 | -91,080.00 | | 资产减值准备（损失以 | 合同资产减值准备 | -86,867,652. ...

证券代码：300253 证券简称：卫宁健康 公告编号：2025-062 债券代码：123104 债券简称：卫宁转债 卫宁健康科技集团股份有限公司 关于公司缴纳税款的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 卫宁健康科技集团股份有限公司（以下简称"公司"）近期对相 关涉税事项开展了自查，现将有关事项公告如下： 一、税收自查的情况 经自查，公司需补缴增值税、城市维护建设税、教育费附加、地 方教育费附加等并缴纳相应滞纳金，合计 5,737.36 万元。 二、补缴税款的情况 截至本公告披露日，公司已将上述税款及滞纳金缴纳完毕，不涉 及税务行政处罚。 三、对公司的影响 根据《企业会计准则第 28 号——会计政策、会计估计变更和差 错更正》，上述补缴税款及滞纳金事项不属于前期会计差错，不涉及 前期财务数据追溯调整。公司补缴上述税款及滞纳金将计入 2025 年 当期损益，预计将影响公司 2025 年度归属于上市公司股东的净利润 5,737.36 万元，最终以 2025 年度经审计的财务报表为准。 特此公告。 卫宁健康科技集团股份有限公司 董 事 会 二〇二五年八 ...